Caption Management, LLC Immuno Gen, Inc. Transaction History

Caption Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$14.09 - $19.87 $149,354 - $210,622	10,600 Added 35.33%	40,600 $644,000
Q2 2023 Aug 14, 2023	BUY	$3.75 - $20.05 $112,500 - $601,500	30,000 New	30,000 $566,000
Q1 2021 May 17, 2021	SELL	$6.5 - $10.53 $241,150 - $390,663	-37,100 Reduced 64.97%	20,000 $163,000
Q4 2020 Feb 16, 2021	BUY	$3.7 - $7.66 $211,270 - $437,386	57,100 New	57,100 $368,000
Q4 2019 Feb 13, 2020	SELL	$2.25 - $5.8 $112,500 - $290,000	-50,000 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$2.22 - $3.39 $66,600 - $101,700	-30,000 Reduced 37.5%	50,000 $121,000
Q2 2019 Aug 13, 2019	BUY	$1.8 - $3.3 $141,840 - $260,040	78,800 Added 6566.67%	80,000 $174,000
Q1 2019 May 14, 2019	SELL	$2.41 - $5.91 $408,615 - $1 Million	-169,550 Reduced 99.3%	1,200 $3,000
Q4 2018 Jan 30, 2019	BUY	$3.94 - $9.7 $368,390 - $906,949	93,500 Added 121.04%	170,750 $819,000
Q3 2018 Nov 14, 2018	BUY	$8.6 - $11.26 $664,350 - $869,835	77,250 New	77,250 $732,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Caption Management, LLC with notifications on news.